title: In vivo 5-HT(6) receptor occupancy by antipsychotic drugs in the rat brain.
abstract: The 5-HT(6) receptor subtype is predominantly expressed in the central nervous system, and preclinical evidence suggests that it plays a critical role in the regulation of molecular pathways underlying cognitive function. Patients with schizophrenia show cognitive impairment as a fundamental symptom, and it is proposed that the procognitive properties of some antipsychotics such as olanzapine and clozapine would be, in part, due to the central blockade of 5-HT(6) receptors. In this study, we characterized the brain 5-HT(6) receptor occupancy of olanzapine, clozapine and chlorpromazine in relation to their pharmacokinetic profiles using in vivo [(3)H]GSK215083 binding assay in rat brain. Oral administration of olanzapine (3mg/kg), clozapine (30mg/kg) and chlorpromazine (30mg/kg) produced significant 5-HT(6) receptor occupancy in the brain, inhibiting radioligand binding by 88, 97 and 81%, respectively. The blood concentrations required to achieve significant occupancy were clinically achievable (9.6, 26.9 and 98.6nM for olanzapine, clozapine and chlorpromazine, respectively). This data provides preclinical evidence to support the hypothesis that brain 5-HT(6) antagonism contributes to the procognitive properties of antipsychotic drugs such as olanzapine and clozapine.
authors: Neural Pathway Discovery Performance Unit, R&D China, GlaxoSmithKline, #03-01/02, The Helios, 11 Biopolis Way, Singapore 138667. kazufumi.2.hirano@gsk.com
authors: Kazufumi
authors: K
authors: Hirano
authors: Kirsten L
authors: KL
authors: Searle
authors: Shabina
authors: S
authors: Nasir
authors: Chiu-Cheong
authors: CC
authors: Aw
authors: Edward R
authors: ER
authors: Browne
authors: A Richard
authors: AR
authors: Rutter
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001569:Benzodiazepines / Q000493:pharmacokinetics / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002746:Chlorpromazine / Q000493:pharmacokinetics / Q000494:pharmacology; D003024:Clozapine / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008297:Male; D000077152:Olanzapine; D010879:Piperazines / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D011985:Receptors, Serotonin; C503990:SB 399885; D013449:Sulfonamides; C097216:serotonin 6 receptor; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine; D002746:Chlorpromazine